Adenosine A1 receptors using 8-dicyclopropylmethyl-1-[11C]methyl-3-propylxanthine PET in Alzheimer’s disease

ObjectiveAdenosine is an endogenous modulator of synaptic functions in the central nervous system. The effects of adenosine are mediated by at least four adenosine receptor subtypes. Decreased density of adenosine A1 receptors, which is a major subtype adenosine receptor in the hippocampus, has been reported in vitro in Alzheimer’s disease. We evaluated adenosine A1 receptor in the brain of elderly normal subjects and patients with Alzheimer’s disease (n = 8 and 6, respectively), using positron emission tomography (PET) and 8- dicyclopropylmethyl-1-[11C]methyl-3-propylxanthine ([11C]MPDX).MethodsA 60-min PET scan with [11C]MPDX was performed. The patients with Alzheimer’s disease also underwent PET with [18F]fluorodeoxyglucose (FDG). The binding potential of [11C]MPDX was quantitatively calculated in the regions of interest (ROIs) placed on the frontal, medial frontal, temporal, medial temporal, parietal, and occipital cortices, striatum, thalamus, cerebellum, and pons. Statistical parametric mapping (SPM2) was used for analysis of [11C]MPDX and FDG-PET.ResultsIn the ROI-based analysis, the binding potential of [11C]MPDX in patients with Alzheimer’s disease was significantly lower in the temporal and medial temporal cortices and thalamus than that in elderly normal subjects (P = 0.038, 0.028, and 0.039, respectively). SPM analysis also showed significant decreased binding potential in the temporal and medial temporal cortices and thalamus in patients with Alzheimer’s disease. FDG uptake was significantly decreased in the temporoparietal cortex and posterior cingulate gyrus.ConclusionsDecreased binding of [11C]MPDX in patients with Alzheimer’s disease was detected in temporal and medial temporal cortices and thalamus. This pattern possibly differed from the hypometabolism pattern of FDG. [11C]MPDX PET is valuable for the detection of degeneration in the temporal and medial temporal cortices and corticothalamic transmission, and may provide a different diagnostic tool from FDG-PET in brain disorders such as Alzheimer’s disease.

[1]  B. Fredholm,et al.  How does adenosine inhibit transmitter release? , 1988, Trends in pharmacological sciences.

[2]  D. Gold,et al.  Expenditures in caring for patients with dementia who live at home. , 1993, American journal of public health.

[3]  Sue J. Kang,et al.  Glucose metabolism in early onset versus late onset Alzheimer's disease: an SPM analysis of 120 patients. , 2005, Brain : a journal of neurology.

[4]  K. Ishii,et al.  Comparison of gray matter and metabolic reduction in mild Alzheimer’s disease using FDG-PET and voxel-based morphometric MR studies , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  J. Yesavage,et al.  Cognitive function and the costs of Alzheimer disease. An exploratory study. , 1997, Archives of neurology.

[6]  Tetsuya Mori,et al.  Differences in cerebral metabolic impairment between early and late onset types of Alzheimer's disease , 2002, Journal of the Neurological Sciences.

[7]  R. Corradetti,et al.  Adenosine decreases aspartate and glutamate release from rat hippocampal slices. , 1984, European journal of pharmacology.

[8]  R. Zahn,et al.  Hemispheric asymmetries of hypometabolism associated with semantic memory impairment in Alzheimer's disease: a study using positron emission tomography with fluorodeoxyglucose-F18 , 2004, Psychiatry Research: Neuroimaging.

[9]  T. Dunwiddie,et al.  The Role and Regulation of Adenosine in the Central Nervous System , 2022 .

[10]  T. Dunwiddie.  The physiological role of adenosine in the central nervous system. , 1985, International review of neurobiology.

[11]  S. Rose,et al.  Gray and white matter changes in Alzheimer's disease: A diffusion tensor imaging study , 2008, Journal of magnetic resonance imaging : JMRI.

[12]  J. Phillis,et al.  The role of adenosine and its nucleotides in central synaptic transmission , 1981, Progress in Neurobiology.

[13]  R. Kalaria,et al.  Hippocampal adenosine A1 receptors are decreased in Alzheimer's disease , 1990, Neuroscience Letters.

[14]  Truls Østbye,et al.  Net economic costs of dementia in Canada. , 1994, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[15]  C. Cotman,et al.  Reduced density of adenosine A1 receptors and preserved coupling of adenosine A1 receptors to G proteins in alzheimer hippocampus: A quantitative autoradiographic study , 1993, Neuroscience.

[16]  G. V. Van Hoesen,et al.  Perforant pathway changes and the memory impairment of Alzheimer's disease , 1986, Annals of neurology.

[17]  Yuichi Kimura,et al.  Quantitative analysis of adenosine A1 receptors in human brain using positron emission tomography and [1-methyl-11C]8-dicyclopropylmethyl-1-methyl-3-propylxanthine. , 2004, Nuclear medicine and biology.

[18]  B. Schoenberg,et al.  Epidemiology of Alzheimer's disease and other dementing illnesses. , 1986, Journal of chronic diseases.

[19]  J. Korf,et al.  Reduction of adenosine A1-receptors in the perforant pathway terminal zone in Alzheimer hippocampus , 1991, Neuroscience Letters.

[20]  B B Fredholm,et al.  Modulation of neurotransmission by purine nucleotides and nucleosides. , 1980, Biochemical pharmacology.

[21]  J. Fastbom,et al.  Adenosine A1 receptors in the human brain: A quantitative autoradiographic study , 1987, Neuroscience.

[22]  R. Snaith,et al.  The Hospital Anxiety and Depression Scale , 1983 .

[23]  K. Holmen,et al.  Prevalence of Alzheimer's disease and other dementias in an elderly urban population , 1991, Neurology.

[24]  Yuichi Kimura,et al.  Imaging of adenosine A1 receptors in the human brain by positron emission tomography with [11C]MPDX , 2003, Annals of nuclear medicine.

[25]  J. Costentin,et al.  Adenosine A2A receptors and depression , 2003, Neurology.

[26]  J. Baron,et al.  Relations between hypometabolism in the posterior association neocortex and hippocampal atrophy in Alzheimer's disease: a PET/MRI correlative study , 2001, Journal of neurology, neurosurgery, and psychiatry.

[27]  Helmut L. Haas,et al.  Functions of neuronal adenosine receptors , 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.

[28]  G. Alexander,et al.  Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease , 1998, Neurology.

[29]  M. D. de Leon,et al.  Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  E. Hall-Craggs,et al.  The significance of longitudinal fibre division in skeletal muscle. , 1972, Journal of the neurological sciences.

[31]  Kunihiro Chihara,et al.  Omission of serial arterial blood sampling in neuroreceptor imaging with independent component analysis , 2005, NeuroImage.

[32]  R. Faull,et al.  Alzheimer's disease: Changes in hippocampal N-methyl-d-aspartate, quisqualate, neurotensin, adenosine, benzodiazepine, serotonin and opioid receptors—an autoradiographic study , 1990, Neuroscience.

[33]  M. Kiyosawa,et al.  Evaluation of carbon-11 labeled KF15372 and its ethyl and methyl derivatives as a potential CNS adenosine A1 receptor ligand. , 1997, Nuclear medicine and biology.

[34]  B. Ardekani,et al.  A Fully Automatic Multimodality Image Registration Algorithm , 1995, Journal of computer assisted tomography.

[35]  Yuichi Kimura,et al.  Adenosine A1 receptor mapping of the human brain by PET with 8-dicyclopropylmethyl-1-11C-methyl-3-propylxanthine. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[36]  R Brookmeyer,et al.  Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. , 1998, American journal of public health.

[37]  D. Bennett,et al.  White matter changes in mild cognitive impairment and AD: A diffusion tensor imaging study , 2006, Neurobiology of Aging.

[38]  A. Dolphin,et al.  An adenosine agonist inhibits and a cyclic AMP analogue enhances the release of glutamate but not GABA from slices of rat dentate gyrus , 1983, Neuroscience Letters.

[39]  S. Hourani,et al.  Adenosine receptor subtypes. , 1993, Trends in pharmacological sciences.

[40]  M. Dragunow,et al.  Localization of adenosine A1-receptors to the terminals of the perforant path , 1988, Brain Research.

[41]  J B Poline,et al.  Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease. , 2007, Brain : a journal of neurology.

[42]  Tadashi Nariai,et al.  Preclinical studies on [11C]MPDX for mapping adenosine A1 receptors by positron emission tomography , 2002, Annals of nuclear medicine.

[43]  D. Lubitz.  Adenosine in the treatment of stroke: yes, maybe, or absolutely not? , 2001 .

[44]  G Burnstock,et al.  Nomenclature and Classification of Purinoceptors* , 2005 .

[45]  L. Mosconi,et al.  Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease , 2005, European Journal of Nuclear Medicine and Molecular Imaging.